LearnMay 26, 20264 min read

The 2026 Update in Crohn’s Treatment: What Selective IL-23 Inhibitors Mean for Patients

Breakthrough in Crohn’s Treatment

If you or someone you love is managing moderately to severely active Crohn’s disease, you already know how exhausting the journey can be. Finding a treatment that brings true, long-term relief often feels like a frustrating game of trial and error.

For a long time, anti-TNF therapies (like Remicade and Humira) have been the standard go-to options. But the tough reality is that many people either don’t respond to them, or find that they stop working after a while.

Fortunately, the world of gastroenterology is experiencing an incredibly exciting shift. A newer class of treatments, called selective IL-23 (p19) inhibitors, is changing how many people with Crohn’s are treated. In trials they helped heal the gut lining in many people, and some can be started at home.

Let’s look at what selective IL-23 targeting is and what the trials found.

1. The Science of Precision: Why “Selective” Targeting is a Big Deal

To understand why this breakthrough is making waves, it helps to look at how our immune system triggers gut inflammation.

Older biologics, like Ustekinumab (Stelara), work by targeting a protein subunit called p40. This subunit is shared by two different inflammatory messengers in the body: Interleukin-12 (IL-12) and Interleukin-23 (IL-23).

However, modern research has shown us something incredibly important:

  • IL-23 is the real troublemaker here. It’s a primary driver of the chronic, destructive inflammation in the gut for Crohn’s patients.
  • IL-12 actually does a lot of good! It helps your body defend itself against certain infections and other illnesses.

By shifting to a selective IL-23 inhibitor, newer medications zero in exclusively on the p19 subunit of IL-23. This leaves your helpful IL-12 completely free to keep protecting you. Think of it as a highly focused, precise strike: it shuts down the specific inflammation in your gut while sparing other vital parts of your immune defense.

2. Meet the Modern Options: Risankizumab and Guselkumab

Today, at least three selective IL-23 inhibitors are approved for Crohn’s: risankizumab, guselkumab and mirikizumab (Omvoh, approved in January 2025). Here are the first two in more detail:

Risankizumab (Skyrizi)

Approved for Crohn’s in 2022, Risankizumab was the pioneer of this class. It is given through an initial intravenous (IV) phase at a clinic, followed by at-home maintenance injections every 8 weeks. In trials it helped many people feel better and showed healing of the bowel lining.

Guselkumab (Tremfya)

Guselkumab was approved by the FDA for Crohn’s disease in 2025, backed by Phase 3 clinical trial data:

  • The GALAXI-2 and GALAXI-3 Trials: These large studies evaluated adults with moderately to severely active Crohn’s. The results showed that Guselkumab helped many people reach clinical remission and healing of the gut lining, including some who had already tried other biologics.
  • The GRAVITI Study: This trial tested a subcutaneous-only induction and maintenance plan, meaning injections under the skin from day one instead of starting with an IV infusion in a clinic. It found that this approach worked well and raised no new safety concerns.

3. What This Means for Your Everyday Life

All of this clinical data translates into three very real, practical benefits for patients:

  • Deep Healing (Not Just Feeling Better): In the past, “remission” just meant your symptoms went away. Today, doctors aim for true mucosal healing, literally repairing the physical tissue of the gut lining. Selective IL-23 inhibitors have shown healing of the gut lining in many trial participants. Doctors hope this lowers the risk of long-term problems and surgery, but that is still being studied.
  • Fewer Trips to the Infusion Center: Traditional biologics often require you to sit in an outpatient clinic for hours to get your starter doses. Thanks to the GRAVITI approach, Guselkumab can now be started with injections at home, if your doctor agrees. Risankizumab still starts with IV doses in a clinic.
  • A Second Chance: If your body hasn’t responded well to classic therapies like Remicade or Humira, don’t lose heart. Trials show that selective IL-23 inhibitors can help some patients who have already been through other treatments. They do not work for everyone.

Quick Comparison: Risankizumab vs. Guselkumab

FeatureRisankizumab (Skyrizi)Guselkumab (Tremfya)
How it WorksTargets IL-23 (p19 subunit)Targets IL-23 (p19 subunit)
Starting Out (Induction)Intravenous (IV) at Weeks 0, 4, and 8Choice of Subcutaneous (SC) injections OR IV
Staying Well (Maintenance)At-home injection every 8 weeksAt-home injection every 4 or 8 weeks
The Biggest PerkApproved since 2022, so it has been used longer.The GRAVITI approach lets many people start with injections at home.

The Takeaway

Selective IL-23 inhibitors such as risankizumab, guselkumab and mirikizumab give people and doctors more choices. They are more targeted than some older drugs, but they still have risks, such as infections, and your doctor will check you first, for example for tuberculosis and hepatitis B.

If your current treatment plan is falling short, or if you are tired of the logistical headache of traveling to infusion clinics, it’s a great time to advocate for your health. Schedule a friendly chat with your gastroenterologist and ask if a selective IL-23 inhibitor, and specifically an at-home injection routine, might be the right key to helping you heal and get your quality of life back.

💡 A Quick Note: This post is for educational and informational purposes only and does not take the place of professional medical advice. Always talk with your doctor or healthcare team before making changes to your treatment plan.

Get Healthy Crohns on Google Play

Track food, sleep, meds and symptoms privately on your phone.

An iPhone version is currently in production.

Or get new articles and app updates by email:

I am not a doctor. This is not medical advice. Check with your care team before changing treatment, diet or supplements.